BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3304 related articles for article (PubMed ID: 32940187)

  • 1. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
    Syam AF; Pitoyo CW; Suhendro S; Zulkarnain B; Indrasari ND; Aditianingsih D; Irawan C; Susilo A; Rumende CM; Wijaya IP; Ibrahim F; Rasmin M; Alwi I; Makmun D
    Acta Med Indones; 2021 Apr; 53(2):194-201. PubMed ID: 34251348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
    Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
    Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
    J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-cytokine therapy in novel coronavirus disease (COVID-19) – the first administration of tocilizumab in Hungary at a department of infectology].
    Lakatos B; Gopcsa L; Gondos E; Riczu A; Várnai Z; Nagy É; Molnár E; Bekő G; Bobek I; Reményi P; Szlávik J; Sinkó J; Vályi-Nagy I
    Orv Hetil; 2020 Jun; 161(26):1070-1077. PubMed ID: 32541085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.
    Cala-García JD; Sierra-Bretón JD; Cavelier-Baiz JE; Faccini-Martínez ÁA; Pérez-Díaz CE
    Immunotherapy; 2020 Oct; 12(15):1127-1132. PubMed ID: 32664810
    [No Abstract]   [Full Text] [Related]  

  • 8. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
    Gokhale Y; Mehta R; Kulkarni U; Karnik N; Gokhale S; Sundar U; Chavan S; Kor A; Thakur S; Trivedi T; Kumar N; Baveja S; Wadal A; Kolte S; Deolankar A; Pednekar S; Kalekar L; Padiyar R; Londhe C; Darole P; Pol S; Gokhe SB; Padwal N; Pandey D; Yadav D; Joshi A; Badgujar H; Trivedi M; Shah P; Bhavsar P
    BMC Infect Dis; 2021 Mar; 21(1):241. PubMed ID: 33673818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
    Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
    Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.
    Khiali S; Khani E; Entezari-Maleki T
    J Clin Pharmacol; 2020 Sep; 60(9):1131-1146. PubMed ID: 32557541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
    Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
    Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
    Chakraborty C; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Agoramoorthy G
    J Med Virol; 2020 Nov; 92(11):2260-2262. PubMed ID: 32462717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunopathogenesis and treatment of cytokine storm in COVID-19.
    Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
    Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
    Zhang Y; Zhong Y; Pan L; Dong J
    Drug Discov Ther; 2020; 14(2):100-102. PubMed ID: 32378647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.
    Birlutiu V; Birlutiu RM; Chicea L
    Medicine (Baltimore); 2021 May; 100(18):e25832. PubMed ID: 33950993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19.
    Ali A; Kamjani MH; Kesselman MM
    Recent Pat Antiinfect Drug Discov; 2020; 15(2):104-112. PubMed ID: 32962623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposed Tocilizumab in Patients with Severe COVID-19.
    Tian J; Zhang M; Jin M; Zhang F; Chu Q; Wang X; Chen C; Yue H; Zhang L; Du R; Zhao D; Zeng Z; Zhao Y; Liu K; Wang M; Hu K; Miao X; Zhang H
    J Immunol; 2021 Feb; 206(3):599-606. PubMed ID: 33298617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.
    Zhang C; Wu Z; Li JW; Zhao H; Wang GQ
    Int J Antimicrob Agents; 2020 May; 55(5):105954. PubMed ID: 32234467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series.
    Tenda ED; Andrian S; Albert S; Asaf MM; Pitoyo CW; Setiati S; Subekti I
    Acta Med Indones; 2021 Jul; 53(3):319-325. PubMed ID: 34611072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of Covid-19 cytokine storm by tocilizumab.
    Boretti A; Banik B
    J Med Virol; 2022 Mar; 94(3):823-828. PubMed ID: 34617604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 166.